Ligand Pharms Glucagon
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI, a dual endothelin and angiotensin II receptor antagonist for immunoglobulin A nephropathy; Ohtuvayre for r… Read more
Ligand Pharms Glucagon (LGNXZ) - Total Liabilities
Latest total liabilities as of June 2025: $120.08 Million USD
Based on the latest financial reports, Ligand Pharms Glucagon (LGNXZ) has total liabilities worth $120.08 Million USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Ligand Pharms Glucagon - Total Liabilities Trend (2002–2024)
This chart illustrates how Ligand Pharms Glucagon's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Ligand Pharms Glucagon Competitors by Total Liabilities
The table below lists competitors of Ligand Pharms Glucagon ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cerillion PLC
LSE:CER
|
UK | GBX15.66 Million |
|
FERRAGAMO - Dusseldorf Stock Exchang
DU:S9L
|
Germany | €1.09 Billion |
|
Florence One Capital Inc.
V:FONC-P
|
Canada | CA$24.48K |
|
Edel AG
HM:EDL
|
Germany | €142.63 Million |
Liability Composition Analysis (2002–2024)
This chart breaks down Ligand Pharms Glucagon's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.45 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ligand Pharms Glucagon's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ligand Pharms Glucagon (2002–2024)
The table below shows the annual total liabilities of Ligand Pharms Glucagon from 2002 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $111.33 Million | +29.00% |
| 2023-12-31 | $86.30 Million | -47.75% |
| 2022-12-31 | $165.18 Million | -65.33% |
| 2021-12-31 | $476.43 Million | -27.01% |
| 2020-12-31 | $652.76 Million | -10.30% |
| 2019-12-31 | $727.68 Million | -3.21% |
| 2018-12-31 | $751.86 Million | +132.87% |
| 2017-12-31 | $322.86 Million | +24.04% |
| 2016-12-31 | $260.30 Million | -2.06% |
| 2015-12-31 | $265.78 Million | +13.77% |
| 2014-12-31 | $233.62 Million | +323.99% |
| 2013-12-31 | $55.10 Million | -29.15% |
| 2012-12-31 | $77.78 Million | -26.18% |
| 2011-12-31 | $105.36 Million | +46.20% |
| 2010-12-31 | $72.06 Million | -44.45% |
| 2009-12-31 | $129.72 Million | -23.46% |
| 2008-12-31 | $169.47 Million | +28.56% |
| 2007-12-31 | $131.82 Million | -53.97% |
| 2006-12-31 | $286.36 Million | -30.61% |
| 2005-12-31 | $412.69 Million | +3806.23% |
| 2003-12-31 | $10.56 Million | -62.85% |
| 2002-12-31 | $28.44 Million | -- |